All In Biotech

Investigational drug · Phase 2

DS-3939a

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

2

Any phase or sponsor naming "DS-3939a"

First trial start

2023

Aug 18, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "DS-3939a", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Solid Tumor
  • Locally Advanced Non-Small Cell Lung Cancer
  • Metastatic Non-Small Cell Lung Cancer
  • Advanced Solid Tumor
  • Metastatic Solid Tumor

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "DS-3939a" as an intervention, largest first.

All trials
  • Daiichi SankyoDaiichi Sankyo (DSNKY)

    NCT05875168 · 590 participants (planned) · Start Aug 18, 2023 · Primary completion Aug 11, 2028

    Drug: DS-3939a · For: Advanced Solid Tumor; Metastatic Solid Tumor

    Sites: Sarasota, Florida; Locust Grove, Georgia; Westwood, Kansas · 61 sites in all

  • Daiichi SankyoDaiichi Sankyo (DSNKY)

    NCT07739966 · 400 participants (planned) · Start Oct 13, 2026 · Primary completion Jul 31, 2030

    Drug: DS-3939a; Pembrolizumab and 3 more · For: Solid Tumor; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer

    Sites: Fayetteville, Arkansas; Los Angeles, California; Tampa, Florida · 76 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Solid Tumor

  • BMS-986507BL-B01D1, Iza-brenPhase 351 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma

  • SintilimabIBI308Phase 321 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma

  • IfebemtinibIN10018, BI853520Phase 311 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer

  • JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials

    Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor

  • FavezelimabMK-4280, MK-4820APhase 39 trials

    Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors

  • Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma

  • PD-1 inhibitorPhase 38 trials

    BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)

  • RC148Phase 38 trials

    RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Daiichi Sankyo.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.